[Cardiovascular risk and inflammatory markers in patients with hypertension].
Arterial hypertension (AH) is one of the main risk factors of negative cardiovascular (CVR) events and the complex evaluation of CVR is necessary for the successful treatment of patients with AH. Simultaneously CVR increases when the inflammatory markers levels are elevated. The aim of study was to evaluate the frequency of CVR factors presence and their relation to the inflammatory markers in patients with AH. The study was conducted in group of 144 patients (99 men, mean age 45.2 years) with AH and no other diagnosed cardiovascular diseases. The clinical assessment included: i.e. fasting glucose (FG), total cholesterol (T-C), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), triglycerides (TG) and inflammatory markers: fibrinogen, high-sensitive C-reactive protein (hsCRP) and leukocytes count (WBC). CVR was assessed based on the presence of the risk factors included in the ESC guidelines. Dylipidemia was observed in over 90% of patients in the study group (most often as the elevated level of T-C and LDL-C), abdominal obesity in 54.9%, more than 3 CVR factors in over 70% and increased levels of at least one of inflammatory markers in 40.3% of patients (most often hs-CRP - 35.4%). The statistically significant correlations between anthropometric parameters (BMI, waist cirfumference), laboratory parameters (HDL-C, TG) and inflammatory markers were observed, the strongest for BMI versus hs-CRP (r = 0.42, p < 0.000001). In the logic regression analysis the factors increasing the probability of the elevated inflammatory activity turned out to be: abdominal obesity - OR 3.05 (95% CI: 1.49 - 12.22; p = 0.002); BMI ≥ 30 kg/m2 - OR 3.18 (95% CI: 1.57 - 6.44; p = 0.0012) and the presence of more than 3 risk factors - OR 2.57 (95% CI: 1.13 - 5.83; p = 0.023). The increased level of inflammatory markers is related to the complex metabolic disturbances and the assessment of the activation of inflammatory process (especially hsCRP) can be useful in the complex CVR evaluation and profound defining of therapeutical goals.